Herpes Zoster: the rationale for the introduction of vaccination in Italy.

摘要: Herpes Zoster (HZ) and its main complication, post-herpetic neuralgia (PHN), represent an important public health issue because of their relevant burden within older adult population the actual suboptimal therapeutic management diseases. Incidences HZ PHN are comparable all over world closely related with age. Epidemiological data collected in Italy about complications confirmed trend registered North America Europe. Moreover is exacerbated by a significant economic impact to both direct indirect costs. Since 2006 live, attenuated varicella zoster virus vaccine, that contains VZV Oka strain [Zostavax, Merck & Co., Inc.], was licensed for prevention adults aged ≥ 60 years. 2011, licensure has been extended between 50 59 The vaccine demonstrated good immunogenicity, efficacy safety profiles two pivotal phase III clinical trials effectiveness further after licensure. Pharmaco-economic studies concluded cost-effective most European countries generally supported value this vaccination. actually recommended USA, Canada several countries. opportunity reduce these diseases recommendation vaccination have evaluated suggested also our Country some Regions recently introduced immunization plan. If results, already obtained other countries, will be Italian pilot experiences, programs should made uniform order ensure equitable offer preventive tool.